Coherus Biosciences | CHRS - Loan Capital


Coherus Biosciences reported $51.08M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Acadia Pharmaceuticals USD 0 0 Mar/2025
Akebia Therapeutics USD 36.39M 11.85M Mar/2026
ALKERMES USD 1.48B 7.23M Jun/2026
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.89B 1.88B Mar/2026
Baxter International USD 8.62B 6M Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Fujifilm JPY 607.03B 35.21B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Merck USD 46.67B 77M Mar/2026
Myriad Genetics USD 120.7M 400K Jun/2026
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.62B 17.5M Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Teva Pharmaceutical Industries USD 12.09B 1.92B Jun/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xencor USD 82.12M 5.64M Mar/2026
Zoetis USD 9.04B 3M Mar/2026